Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jade Bath

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
The Journal of Clinical Investigation|August 22, 2024
Mucins protect against Streptococcus pneumoniae virulence by suppressing pneumolysin expressionJade Bath, Elisabet Bjånes, Cengiz Goekeri, et al.
Current Biology : CB|August 10, 2021
MucusAbigail McShane, Jade Bath, Ana M Jaramillo, et al.
Plos Pathogens|October 28, 2022
Piperaquine-resistant PfCRT mutations differentially impact drug transport, hemoglobin catabolism and parasite physiology in Plasmodium falciparum asexual blood stagesJohn Okombo, Sachel Mok, Tarrick Qahash, et al.
ACS Infectious Diseases|October 31, 2018
Identification and Mechanistic Understanding of Dihydroorotate Dehydrogenase Point Mutations in Plasmodium falciparum that Confer in Vitro Resistance to the Clinical Candidate DSM265John White, Satish K Dhingra, Xiaoyi Deng, et al.
The Lancet. Infectious Diseases|June 18, 2018
Antimalarial activity of single-dose DSM265, a novel plasmodium dihydroorotate dehydrogenase inhibitor, in patients with uncomplicated Plasmodium falciparum or Plasmodium vivax malaria infection: a proof-of-concept, open-label, phase 2a studyAlejandro Llanos-Cuentas, Martin Casapia, Raúl Chuquiyauri, et al.
Journal of Medicinal Chemistry|April 20, 2021
Potent Antimalarials with Development Potential Identified by Structure-Guided Computational Optimization of a Pyrrole-Based Dihydroorotate Dehydrogenase Inhibitor SeriesMichael J Palmer, Xiaoyi Deng, Shawn Watts, et al.
Science Translational Medicine|July 22, 2021
The antimalarial MMV688533 provides potential for single-dose cures with a high barrier to <i>Plasmodium falciparum</i> parasite resistanceJames M Murithi, Cécile Pascal, Jade Bath, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
The Journal of Clinical Investigation|August 22, 2024
Mucins protect against Streptococcus pneumoniae virulence by suppressing pneumolysin expressionJade Bath, Elisabet Bjånes, Cengiz Goekeri, et al.
Current Biology : CB|August 10, 2021
MucusAbigail McShane, Jade Bath, Ana M Jaramillo, et al.
Plos Pathogens|October 28, 2022
Piperaquine-resistant PfCRT mutations differentially impact drug transport, hemoglobin catabolism and parasite physiology in Plasmodium falciparum asexual blood stagesJohn Okombo, Sachel Mok, Tarrick Qahash, et al.
ACS Infectious Diseases|October 31, 2018
Identification and Mechanistic Understanding of Dihydroorotate Dehydrogenase Point Mutations in Plasmodium falciparum that Confer in Vitro Resistance to the Clinical Candidate DSM265John White, Satish K Dhingra, Xiaoyi Deng, et al.
The Lancet. Infectious Diseases|June 18, 2018
Antimalarial activity of single-dose DSM265, a novel plasmodium dihydroorotate dehydrogenase inhibitor, in patients with uncomplicated Plasmodium falciparum or Plasmodium vivax malaria infection: a proof-of-concept, open-label, phase 2a studyAlejandro Llanos-Cuentas, Martin Casapia, Raúl Chuquiyauri, et al.
Journal of Medicinal Chemistry|April 20, 2021
Potent Antimalarials with Development Potential Identified by Structure-Guided Computational Optimization of a Pyrrole-Based Dihydroorotate Dehydrogenase Inhibitor SeriesMichael J Palmer, Xiaoyi Deng, Shawn Watts, et al.
Science Translational Medicine|July 22, 2021
The antimalarial MMV688533 provides potential for single-dose cures with a high barrier to <i>Plasmodium falciparum</i> parasite resistanceJames M Murithi, Cécile Pascal, Jade Bath, et al.
Pageof 1